- ISIN
- US03940C1009
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 4, 2022
Highlights
- EPS (TTM)
- -$3.86
- Total Revenue (TTM)
- $35.90M
- Gross Profit (TTM)
- $810.00K
- EBITDA (TTM)
- -$209.52M
- Year Range
- $60.36 - $115.13
- Target Price
- $110.42
- ROA (TTM)
- -49.25%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ACLX Performance Chart
Loading charts...
Returns By Period
Arcellx Inc
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ACLX Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.77% | 66.58% | 0.91% | 0.22% | 76.49% | ||||||||
| 2025 | -11.16% | -4.86% | 1.20% | -0.99% | -4.45% | 6.11% | 8.41% | -2.80% | 18.32% | 9.93% | -19.43% | -10.33% | -14.98% |
| 2024 | 11.42% | 6.44% | 5.67% | -28.08% | 3.96% | 6.13% | 11.99% | 11.21% | 21.49% | 0.91% | 4.51% | -12.92% | 38.18% |
| 2023 | 7.84% | -16.16% | 10.00% | 38.53% | 3.44% | -28.38% | 8.32% | 4.64% | 0.11% | -1.76% | 49.02% | 5.65% | 79.15% |
| 2022 | 13.93% | -26.75% | -22.04% | 10.80% | 49.30% | 14.66% | -13.31% | 4.45% | 25.09% | -15.08% | 55.37% | 84.40% |
Benchmark Metrics
Arcellx Inc has an annualized alpha of 80.21%, beta of 0.87, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since February 07, 2022.
- This stock captured 136.82% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -71.99%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 80.21%
- Beta
- 0.87
- R²
- 0.04
- Upside Capture
- 136.82%
- Downside Capture
- -71.99%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Arcellx Inc (ACLX) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Arcellx Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arcellx Inc was 62.33%, occurring on May 18, 2022. Recovery took 14 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -62.33%May 2022 | 2mo 18d | 21d | 3mo 9dMar 2022 - Jun 2022 |
2025 selloff2025 | -50.44%May 2025 | 5mo 25d | 9mo 23d | 1y 3moNov 2024 - Feb 2026 |
Bear market2022 | -38.52%Jun 2022 | 3d | 5mo 26d | 5mo 29dJun 2022 - Dec 2022 |
2023 bear market2023 | -33.53%Jun 2023 | 1mo 19d | 4mo 11d | 6moMay 2023 - Nov 2023 |
2024 bear market2024 | -32.32%May 2024 | 1mo 20d | 4mo 2d | 5mo 22dMar 2024 - Sep 2024 |
Drawdown Indicators
| ACLX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -0.74% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Arcellx Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Arcellx Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ACLX relative to other companies in the Biotechnology industry. Currently, ACLX has a P/S ratio of 180.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ACLX
Add Arcellx Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ACLX